Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs -- an approach termed chemoprophylaxis vaccination. A Phase 2 clinical trial of the vaccine is now underway in Mali, a malaria-endemic country.
from Latest Science News -- ScienceDaily https://ift.tt/360Gg7S
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment